In a letter to physicians, the company noted that there is an increased risk of blockages in the bloodstream depending on the ...

The FDA has issued an alert about a potentially high-risk issue involving models of Boston Scientific’s Watchman Access Systems, which are used to provide vascular and transseptal access during ...

Key Takeaways Two Boston Scientific heart devices have been linked to serious injuries and deathsOne device may fail to ...

Boston Scientific is recommending updates to the instructions for use to minimize the issue, which has been tied to 17 deaths ...

A company spokesperson said in a statement to MedTech Dive that direct causation between the deaths and calcification of the ...

Boston Scientific Corporation (NYSE:BSX) is one of the most profitable growth stocks to buy according to billionaires. On ...

Boston Scientific reported Q2 2025 sales of over $5bn, a 22.8% rise on Q2 2024, besting previous growth estimates of 19.5% at the high end.

Investing.com -- Boston Scientific (NYSE: BSX) stock fell 1.8% after the U.S. Food and Drug Administration (FDA) disclosed a potentially high-risk issue with the company’s defibrillation leads that ...

Former FDA Director David Feigal joins Keyron as Head of Regulatory Affairs Dr Joyce Peetermans (ex-Boston Scientific) joins as Acting CTO Christopher Rowland (ex-Boston Scientific) ...

“We are very pleased to receive FDA approval for these advanced devices, and excited about the potential they bring to our bradycardia business,” said Joe Fitzgerald, senior vice president and ...

A dozen lawsuits have been filed over spinal cord stimulators, which are medical devices surgically implanted to reduce chronic back pain. The suits name device manufacturers, such as Abbott and ...

Boston Scientific received FDA 510(k) clearance for its SpyGlass DS Direct Visualization System. The system is cleared for use in the diagnosis and treatment of pancreatico-biliary disease. The first ...